Physician profile
Basma Ataallah
NPI 1518462506
$949.68
in general payments reported to CMS, 2019-2025
18 companies · $409 in 2025
The $409 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $64.49 · 2024: $477 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.85 | 2024-2025 | Ozempic, Rybelsus |
| Radius Health, INC. | $134.31 | 2024-2025 | Tymlos |
| Corcept Therapeutics | $89.17 | 2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $84.22 | 2025 | Strensiq |
| Lilly USA, LLC | $82.30 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.28 | 2023-2025 | Jardiance, Cyltezo |
| Amgen INC. | $69.92 | 2025 | Evenity, Tepezza |
| Inspire Medical Systems, INC. | $58.14 | 2024-2025 | Inspire |
| Abbvie INC. | $38.97 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2025 | |
| Alvogen INC | $20.70 | 2025 | Teriparatide |
| Ibsa Pharma INC. | $20.30 | 2023 | Licart, Tirosint |
| Insulet Corporation | $17.97 | 2025 | Omnipod |
| Currax Pharmaceuticals LLC | $17.03 | 2023 | Contrave |
| Sequel Med Tech, LLC | $15.41 | 2025 | Twiist |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $15.23 | 2024 | |
| Averitas Pharma INC. | $15.21 | 2024 | Qutenza |
| Halozyme INC | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basma Ataallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.